The groundbreaking treatment of this peptide represents a exciting breakthrough in the care of diabetes mellitus type 2. Unlike existing drugs, tirzepatide affects dual pathways – the GLP-1 hormone and glucose-dependent insulinotropic polypeptide (GIP) – providing improved glucose management and